Skip to content

Post Market Clinical Follow-up study of the use of the vaginal cream Remifemin® FeuchtCreme (RFC)

Post Market Clinical Follow-up study of the use of the vaginal cream Remifemin® FeuchtCreme (RFC) - SB-VMP 0212

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00006888
Enrollment
480
Registered
2014-10-20
Start date
2014-10-22
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complaints due to dryness of the vagina and the outer genital area (dry feeling, burning sensation, pain during sexual intercourse, or itching), as developed, for example, during the menopause. Facilitation of sexual intercourse. Physical support of the healing process of minor wounds and small inflammations of the vaginal skin. N89.8

Interventions

Group 1: Non-interventional study. Documentation of data of patients who are prescribed Remifemin® FeuchtCreme and use it discontinuously as needed (with or without applicator according to the instruc

Sponsors

Schaper & Brümmer GmbH & Co. KG
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - The use of the vaginal cream RFC for vaginal dryness is indicated. - The vaginal cream RFC is used in line with the instructions for use. - No restrictions on use of the vaginal cream RFC are recorded. - Written data collection consent has been obtained.

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

MeasureTime frame
Change in physician assessment of vaginal moisture and change in subjective feeling of vaginal dryness (physician interviewing patient) on Date 2 (after approx. 8 weeks) as compared to the baseline value before start of therapy.

Secondary

MeasureTime frame
Change in subjective feeling of complaints and change in physician assessment of symptoms on Date 2 (after approx. 8 weeks) as compared to the baseline value before start of therapy.

Countries

Germany

Contacts

Public ContactJörg Schnitker

Institut für angewandte Statistik Dr. Jörg Schnitker GmbH

info@ias-cro.de0521 / 56 088-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026